Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

183 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
High-Dose Treosulfan and Melphalan as Consolidation Therapy Versus Standard Therapy for High-Risk (Metastatic) Ewing Sarcoma.
Koch R, Gelderblom H, Haveman L, Brichard B, Jürgens H, Cyprova S, van den Berg H, Hassenpflug W, Raciborska A, Ek T, Baumhoer D, Egerer G, Eich HT, Renard M, Hauser P, Burdach S, Bovee J, Bonar F, Reichardt P, Kruseova J, Hardes J, Kühne T, Kessler T, Collaud S, Bernkopf M, Butterfaß-Bahloul T, Dhooge C, Bauer S, Kiss J, Paulussen M, Hong A, Ranft A, Timmermann B, Rascon J, Vieth V, Kanerva J, Faldum A, Metzler M, Hartmann W, Hjorth L, Bhadri V, Dirksen U. Koch R, et al. Among authors: hardes j. J Clin Oncol. 2022 Jul 20;40(21):2307-2320. doi: 10.1200/JCO.21.01942. Epub 2022 Apr 15. J Clin Oncol. 2022. PMID: 35427190 Clinical Trial.
Bone tumors in adolescents and young adults.
Bielack SS, Carrle D, Hardes J, Schuck A, Paulussen M. Bielack SS, et al. Among authors: hardes j. Curr Treat Options Oncol. 2008 Feb;9(1):67-80. doi: 10.1007/s11864-008-0057-1. Epub 2008 May 1. Curr Treat Options Oncol. 2008. PMID: 18449804 Review.
The influence of tumor- and treatment-related factors on the development of local recurrence in osteosarcoma after adequate surgery. An analysis of 1355 patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols.
Andreou D, Bielack SS, Carrle D, Kevric M, Kotz R, Winkelmann W, Jundt G, Werner M, Fehlberg S, Kager L, Kühne T, Lang S, Dominkus M, Exner GU, Hardes J, Hillmann A, Ewerbeck V, Heise U, Reichardt P, Tunn PU. Andreou D, et al. Among authors: hardes j. Ann Oncol. 2011 May;22(5):1228-1235. doi: 10.1093/annonc/mdq589. Epub 2010 Oct 28. Ann Oncol. 2011. PMID: 21030381 Free article.
Risk of recurrence and survival after relapse in patients with Ewing sarcoma.
Stahl M, Ranft A, Paulussen M, Bölling T, Vieth V, Bielack S, Görtitz I, Braun-Munzinger G, Hardes J, Jürgens H, Dirksen U. Stahl M, et al. Among authors: hardes j. Pediatr Blood Cancer. 2011 Oct;57(4):549-53. doi: 10.1002/pbc.23040. Epub 2011 Mar 25. Pediatr Blood Cancer. 2011. PMID: 21442722
Adjuvant therapy for resectable high-risk soft tissue sarcoma: feasibility and efficacy of a sandwich chemoradiotherapy strategy.
Brandts CH, Schulz C, Willich N, Steffen B, Hardes J, Gosheger G, Winkelmann W, Serve H, Heinecke A, Berdel WE, Thomas M. Brandts CH, et al. Among authors: hardes j. Cancer Chemother Pharmacol. 2012 Mar;69(3):613-20. doi: 10.1007/s00280-011-1731-8. Epub 2011 Sep 24. Cancer Chemother Pharmacol. 2012. PMID: 21947168 Clinical Trial.
The ganglioside antigen G(D2) is surface-expressed in Ewing sarcoma and allows for MHC-independent immune targeting.
Kailayangiri S, Altvater B, Meltzer J, Pscherer S, Luecke A, Dierkes C, Titze U, Leuchte K, Landmeier S, Hotfilder M, Dirksen U, Hardes J, Gosheger G, Juergens H, Rossig C. Kailayangiri S, et al. Among authors: hardes j. Br J Cancer. 2012 Mar 13;106(6):1123-33. doi: 10.1038/bjc.2012.57. Epub 2012 Feb 28. Br J Cancer. 2012. PMID: 22374462 Free PMC article.
Management of bone tumours in paediatric oncology.
Bölling T, Hardes J, Dirksen U. Bölling T, et al. Among authors: hardes j. Clin Oncol (R Coll Radiol). 2013 Jan;25(1):19-26. doi: 10.1016/j.clon.2012.07.010. Epub 2012 Aug 21. Clin Oncol (R Coll Radiol). 2013. PMID: 22917543 Review.
183 results